Physician profile
Jeffrey E Dunn
NPI 1639123383
$437,112.88
in general payments reported to CMS, 2019-2025
20 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159K · 2020: $46K · 2021: $45K · 2022: $82K · 2023: $50K · 2024: $25K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Honoraria: $14K · Travel and Lodging: $11K · Food and Beverage: $3,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,501.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,335.00 |
| Honoraria | $13,925.00 |
| Travel and Lodging | $11,038.80 |
| Food and Beverage | $3,552.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $87,667.67 | 2019-2025 | Ocrevus, Enspryng |
| Alexion Pharmaceuticals, INC. | $83,955.61 | 2019-2024 | Ultomiris, Soliris |
| Genzyme Corporation | $62,020.68 | 2019-2025 | |
| Celgene Corporation | $41,879.15 | 2019-2024 | Zeposia |
| Horizon Therapeutics Plc | $39,088.13 | 2021-2023 | Uplizna |
| Biogen, INC. | $30,560.58 | 2019-2022 | |
| Emd Serono, INC. | $17,670.91 | 2023-2024 | Evobrutinib, Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $17,359.59 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $14,435.24 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $12,558.25 | 2021-2023 | Ponvory |
| Tg Therapeutics, INC. | $10,577.84 | 2022-2025 | |
| Genentech, INC. | $5,903.25 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $4,375.00 | 2025 | |
| Vanda Pharmaceuticals INC. | $4,025.00 | 2024 | Ponvory |
| Janssen Scientific Affairs, LLC | $2,407.49 | 2020-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,773.98 | 2024 | Uplizna |
| Banner Life Sciences, LLC | $823.61 | 2021-2023 | |
| Mylan INC. | $30.90 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.